News | April 03, 2026
Cardinal Health boosts production of cutting-edge cancer therapy ingredient
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
This marks a meaningful step in the company's continued expansion in the region
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The approval is backed by results from Lilly’s ATTAIN clinical trial program, which showed significant weight loss among participants
Subscribe To Our Newsletter & Stay Updated
